NEXGEL reports Q4 revenue up 181% to $3.04M, projecting $13M for 2025 despite a negative EPS.

NEXGEL, a company that manufactures hydrogels for medical and cosmetic uses, reported recent quarterly earnings with a negative EPS of $0.08, despite its stock price rising by $0.39 to $3.09 on the earnings announcement day. The firm, with a market cap of about $20.98 million, saw a significant 181% revenue increase in Q4 2024, reaching $3.04 million. For 2025, NEXGEL projects revenue of $13 million and expects to achieve positive EBITDA.